Acquired Company

Sanofi completed acquisition of Inhibrx, Inc. on 5/30/2024 for $30.00 per share in cash, plus one contingent value right per share, representing a total equity value of approximately $1.7 billion.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. Show more

11025 North Torrey Pines Road, La Jolla, La Jolla, CA, 92037, United States

https://inhibrx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.114B

52 Wk Range

$10.80 - $94.56

Previous Close

$76.59

Open

$77.35

Volume

232,001

Day Range

$77.35 - $81.04

Enterprise Value

428.2M

Cash

153.1M

Avg Qtr Burn

-33.82M

Insider Ownership

27.07%

Institutional Own.

84.40%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ozekibart (INBRX-109) (DR5 agonist) Details Advanced or metastatic, unresectable Chondrosarcoma	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INBRX-106 (OX40 agonist) + Keytruda Details Head and neck squamous cell carcinoma	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INBRX-106 Details Non-small cell lung cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ozekibart (INBRX-109) (DR5 agonist) Details Relapsed/refractory Ewing sarcoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ozekibart (INBRX-109) + FOLFIRI Details Metastatic colorectal cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INBRX-105 (PDL1 X 4-1BB tetravalent conditional agonist) +/- Keytruda Details Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.